Amy Kathleen LeBlanc

Director and Senior Scientist

National Cancer Institute
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (16)

Year:

2026

Purpose: Pet dogs spontaneously develop many of the same tumor types as humans, including osteosarcoma. Recent advances in spatial transcriptomics have improved our ability to utilize formalin-fixed paraffin-embedded tissues collected at canine autopsy. These techniques allow the canine model to be investigated alongside murine models to inform human cancer research. Herein, we present the first application of the GeoMx Canine Cancer Atlas to outcome-linked samples from canine patients enrolled in an osteosarcoma clinical trial. Experimental Design: A tissue microarray of primary osteosarcoma samples was assayed using the GeoMx Digital Spatial Profiler. Samples were stratified by disease-free interval (DFI). Patients within the upper and lower tertiles were assigned to the high- (n = 8) and low-DFI (n = 8) groups, respectively. Analyses included the identification of differentially expressed genes, pathway enrichment, and cell deconvolution. Results: Genes enriched in high-DFI tumors included PTEN and CDKN1B. Low-DFI tumors were enriched for NCAM1. Pathways enriched in the low-DFI group included MYC, MTORC1, and oxidative phosphorylation. High-DFI tumors were enriched for IFNα response and allograft rejection pathways, among others. Macrophages and CD8+ T cells were elevated in high-DFI tumors. Conclusions: Gene and pathway enrichment found to be associated with DFI in this study overlap with that described in human patients with osteosarcoma, underscoring the value of the canine model in metastatic osteosarcoma research.

Year:

2025

Osteosarcoma is a rare but aggressive bone tumor that develops spontaneously in human and canine patients and most commonly metastasizes to the lung. The presence of lung metastases significantly decreases the survival rate of patients, with minimal benefit seen with available treatments. Canine osteosarcoma is clinically and molecularly similar to human osteosarcoma and develops approximately ten times more frequently than human osteosarcoma making dogs a promising natural model to study disease progression. The development of new therapies for pulmonary metastases requires an understanding of the interplay between tissue resident cells as well as recruited cell types and how those interactions impact seeding and progression within the new metastatic site. This review explores the tumor microenvironment surrounding pulmonary metastases and how current knowledge in canine and human patients can inform better treatments and outcomes for both populations.

Year:

2025

Year:

2025

Supplementary Figure 1. The distributions of various quality control parameters including percentages of trimmed, stitched, sequencing saturation, nuclei, and negative counts. Additionally, the distribution of segments with respect to the percentage of genes detected and the total number of genes detected in different percentages of segments are shown.

Year:

2025

Purpose: Pet dogs spontaneously develop many of the same tumor types as humans, including osteosarcoma. Recent advances in spatial transcriptomics have improved our ability to utilize formalin-fixed paraffin-embedded tissues collected at canine autopsy. These techniques allow the canine model to be investigated alongside murine models to inform human cancer research. Herein, we present the first application of the GeoMx Canine Cancer Atlas to outcome-linked samples from canine patients enrolled in an osteosarcoma clinical trial. Experimental Design: A tissue microarray of primary osteosarcoma samples was assayed using the GeoMx Digital Spatial Profiler. Samples were stratified by disease-free interval (DFI). Patients within the upper and lower tertiles were assigned to the high- ( n = 8) and low-DFI ( n = 8) groups, respectively. Analyses included the identification of differentially expressed genes, pathway enrichment, and cell deconvolution. Results: Genes enriched in high-DFI tumors included PTEN and CDKN1B . Low-DFI tumors were enriched for NCAM1 . Pathways enriched in the low-DFI group included MYC, MTORC1, and oxidative phosphorylation. High-DFI tumors were enriched for IFNα response and allograft rejection pathways, among others. Macrophages and CD8 + T cells were elevated in high-DFI tumors. Conclusions: Gene and pathway enrichment found to be associated with DFI in this study overlap with that described in human patients with osteosarcoma, underscoring the value of the canine model in metastatic osteosarcoma research.

Year:

2025

Osteosarcoma is the most common malignant bone tumor in young patients and remains a significant clinical challenge, particularly at the metastatic stage. Studies detailing the immunosuppressive mechanisms within the metastatic osteosarcoma microenvironment are needed to elucidate the cellular communities in the metastatic microenvironment that support metastatic growth and to identify therapeutic approaches to target the cross-talk between cancer cells and their microenvironment. In this study, we performed spatial transcriptional profiling on a cohort of osteosarcoma pulmonary metastases from pediatric patients. The data revealed a conserved spatial gene expression pattern resembling a foreign body granuloma, characterized by peripheral inflammatory signaling, fibrocollagenous encapsulation, lymphocyte exclusion, and peritumoral macrophage accumulation. The intratumoral microenvironment of these lesions, however, lacked inflammatory signaling. Exploration of spatially distinct drug–gene interactions identified the CXCR4 signaling axis, which displayed spatial heterogeneity and complexity, as a potential therapeutic target that bridges both the intra- and extratumoral microenvironments. Collectively, this study reveals that metastatic osteosarcoma comprises multiple regionally distinct immunosuppressive microenvironments. Significance: Exploration of spatially resolved microenvironments in metastatic osteosarcoma tissues reveals how the tissue architecture promotes immunosuppression and identifies actionable processes to enhance immunotherapy efficacy.

Year:

2025

Distribution and abundance of genes encoding functional and phenotypic macrophage markers. Clustered dot plots illustrating the spatial distribution of gene encoding different functional and phenotypic macrophage markers within each individual metastatic osteosarcoma specimen. The color bar above each dot plot corresponds to the different spatial clusters displayed on the adjoining spatial cluster maps that are shown for reference (above). Separate color palettes denote the independent clustering analysis of each specimen. Spatial clusters were localized to the extratumoral (black) or intratumoral (gray) microenvironments as depicted in the second color bar.

Year:

2025

Differential gene expression of chemokine/cytokines in primary versus metastatic osteosarcoma specimens. Volcano plot of differentially expressed chemokine and cytokine genes in non-metastatic (black dots) and pulmonary metastases (gray dots) from the Sorenson, and colleagues NanoString IO360 gene expression dataset (27). Horizontal red line indicates significance threshold (q = 0.001). Dots with red outline indicates q

Year:

2025

Chemokine/cytokine antibody array profiling in metastatic osteosarcoma patient specimens and patient derived cell lines. Heatmaps showing normalized protein expression of chemokines and cytokines from (A) an independent cohort of 10 frozen metastatic osteosarcoma specimens and (B) conditioned media from five unrelated patient derived cell lines.

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Collaborators (4)

Peter Choyke

Senior Investigator

National Cancer Institute

UNITED STATES
View details

Jennifer Cotter

Assistant Professor of Clinical Pathology

University of Southern California Norris Comprehensive Cancer Center

UNITED STATES
View details

JAMES CRONK

Assistant Professor

Cincinnati Children's Hospital Medical Center

UNITED STATES
View details

Rosandra Kaplan

Principal Investigator

National Cancer Institute

UNITED STATES
View details